NEW YORK, June 29, 2021 /PRNewswire/ -- DarioHealth Corp.
(Nasdaq: DRIO), a leader in the global digital therapeutics (DTx)
market, presented new clinical research today at the American
Diabetes Association (ADA) 81st Scientific Sessions, the
premier diabetes conference for cutting-edge research and advances
in diabetes care.
Dario's latest research examines the impacts of the company's
artificial intelligence (AI)-driven personalization engine on user
engagement and clinical outcomes for close to 10,000 members. Dario
users were given access to a new product experience designed to
drive better health habits and behaviors. Dario's AI engine
delivered highly personalized interventions to drive user
engagement based on app activity and utilization data. The results
suggest that personalized interventions help users better
understand the relationship between their behaviors and their
health indicators, driving sustainable engagement and better
clinical outcomes. After the new digital experience was introduced,
both engagement and clinical outcomes improved. The research
yielded the following outcomes on 9,794 users given access to the
new product experience:
- User engagement increased by 56% compared to the engagement
baseline of all users before the new digital experience, results
remained stable for at least six months. Average ratios of
high-blood glucose readings (180-400 mg/dL) were reduced by 12%
over six months.
"Consistent self-management of health conditions is one of the
most crucial healthy behaviors we can help our members develop, and
also one of the most difficult. Customizing the experience of
health management with real-time data and feedback to offer
tangible, actionable insights drives better engagement which leads
to positive behavior change and improved clinical outcomes," said
Yifat Hershcovitz, Scientific and Clinical Director of DarioHealth
and lead author of the study.
"This study offers yet more data supporting our personalized
approach as a means to drive sustainable behavior change for
improved clinical outcomes," said Omar
Manejwala, M.D., Chief Medical Officer of DarioHealth and
co-author of the study.
Dario presented a second study at the ADA Scientific Sessions on
the impact of Dario's hyper-personalization platform on diabetes
self-management, evaluating clinical outcomes for 11,101 high-risk
Type 2 diabetic members after 12 months of engagement. The results
were:
- Average ratio of target in-range readings increased
significantly from 28.4% to 54.8%.
- Average number of days between blood glucose readings (Recency)
for Dario members was 3.3 days
For registration inquiries or to find out how to access final
program presentations, visit the ADA Scientific Sessions event
website at
https://professional.diabetes.org/scientific-sessions.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital
therapeutics company revolutionizing how people with chronic
conditions manage their health. DarioHealth offers one of the most
comprehensive digital therapeutics solutions on the market -
covering multiple chronic conditions including diabetes,
hypertension, weight management, musculoskeletal and behavioral
health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic
platform supports more than just an individual's disease. Dario
provides adaptive, personalized experiences that drive behavior
change through evidence-based interventions, intuitive, clinically
proven digital tools, high-quality software, and coaching to help
individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and
engagement creates an unparalleled experience that is highly rated
by users and delivers sustainable results.
The company's cross-functional team operates at the intersection
of life sciences, behavioral science, and software technology and
utilizes a performance-based approach to improve its users'
health.
On the path to better health, Dario makes the right thing to do
the easy thing to do. To learn more about DarioHealth and its
digital health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the company is using
forward-looking statements in this press release when it discusses
the research results and that the results demonstrate that
personalized interventions help users better understand the
relationship between their behaviors and their health indicators,
driving sustainable engagement and better clinical outcomes.
Without limiting the generality of the foregoing, words such as
"plan," "project," "potential," "seek," "may," "will," "expect,"
"believe," "anticipate," "intend," "could," "estimate" or
"continue" are intended to identify forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario™
as described herein) may differ significantly from those set forth
in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine
Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original
content:https://www.prnewswire.com/news-releases/new-research-from-dariohealth-expands-evidence-that-personalized-interventions-impact-health-behaviors-and-improve-user-engagement-301321861.html
SOURCE DarioHealth Corp.